Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.36 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | CES2 | O00748 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LIPA | P38571 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16772861 | 0.82 | ALDH1A1 (0.41) | FAAHCES1CES2TDP1FFAR3 | |
| SCHEMBL23009371 | 0.80 | TDP1 (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL23009526 | 0.80 | LIPA (0.32) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL27872049 | 0.77 | — | — | |
| SCHEMBL12424406 | 0.77 | TDP1 (0.37) | TDP1FFAR3ALDH1A1 | |
| SCHEMBL810063 | 0.77 | — | — | |
| SCHEMBL10176683 | 0.76 | TRPA1 (0.36) | FAAHLIPA | |
| SCHEMBL13545176 | 0.76 | PDK1 (0.35) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL8383362 | 0.76 | PDK1 (0.35) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL3923809 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | FAAH 4717/4885CES1 4009/4885CES2 3644/4885 |
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR3A | FAAH 115/4885CES1 1153/4885CES2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.